DanielJWeisdorfMD

Oncology • Minneapolis, MN

Professor, Medicine, University of Minnesota Medical School

Join to view full profile

Dr. Weisdorf is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weisdorf's full profile

Already have an account?

Office
516 Delaware Street Se
MMC 480, PWB 14-110
Minneapolis, MN 55455
Phone+1 612-624-3101

Fax+1 612-625-6919

Education & Training

University of MinnesotaFellowship, Hematology and Medical Oncology, 1978 - 1981
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1975 - 1978
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1975

Certifications & Licensure

ND State Medical License 2022 - 2025
MN State Medical License 1978 - 2024
IL State Medical License 1976 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Start of enrollment: 2000 Aug 01
Completed
Phase 2
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma Start of enrollment: 2000 Aug 01
Terminated
Phase 2
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease Start of enrollment: 2000 Jan 01
Withdrawn
Phase 2
Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
Completed
Not Applicable
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Stem Cell Transplant for Hematological Malignancy Start of enrollment: 2001 Oct 01
Terminated
Not Applicable
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease Start of enrollment: 2005 Jul 01
Terminated
Phase 2
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Start of enrollment: 1999 Oct 06
Completed
Phase 2
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2006 Jul 26
Terminated
Phase 2, Phase 3
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS Start of enrollment: 2018 Aug 13
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

70 citations
Allogeneic Hematopoietic Cell Transplantation Compared to Chemotherapy Consolidation in older Acute Myeloid Leukemia (AML) Patients 60–75 Years in First Complete Remis...
Celalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun
Leukemia. 2019-11-01
391 citations
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
Shernan G. Holtan, Todd E. DeFor, Aleksandr Lazaryan, Nelli Bejanyan, Mukta Arora
Blood. 2015-02-19
295 citations
Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect
Claudio G. Brunstein, Jeffrey S. Miller, David H. McKenna, Keli L. Hippen, Todd E. DeFor
Blood. 2016-02-25

Journal Articles

Amphiregulin in Intestinal Acute Graft-Versus-Host Disease: A Possible Diagnostic and Prognostic Aid
Brittney Schultz, Bruce R Blazar, Daniel J Weisdorf, Shernan G Holtan, Alexander Khoruts, Armin Rashidi, Margaret L MacMillan, Khalid Amin, Byron P Vaughn, Nature
Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
Narrowing the Gap for Hematopoietic Stem Cell Transplantation in the East-Mediterranean/African Region: Comparison with Global HSCT Indications and Trends
Marcelo Pasquini, Daniel Weisdorf, Nature
Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value in Isolation or with Other Graft-Versus-Host Disease Symptoms as Currently Diagnos...
Margaret MacMillan, Sophie Paczesny, Ran Reshef, Daniel Weisdorf, Haematologica
Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics
Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica
Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft‐Versus‐Host Disease: Analysis of BMT CTN‐0201 and ‐0901 Samples
Armin Rashidi, Edmund K Waller, Bharat Thyagarajan, Claudio Anasetti, Daniel J Weisdorf, Bart L Scott, Bruce R Blazar, British Journal of Haematology
A Phase II/III Randomized, Multicenter Trial of Prednisone /Sirolimus vs Prednisone/Sirolimus/Calcineurin Inhibitor for Treatment of Chronic Graft-Versus-Host Disease:...
Amin M Alousi, Mukta Arora, Luciano J Costa, Aleksandr Lazaryan, Daniel J Weisdorf, Sunil Abhyankar, Eneida R Nemecek, Haematologica
Late Mortality After Allogeneic Blood or Marrow Transplantation in Childhood for Leukemia: A Report from the Blood or Marrow Transplant Survivor Study-2
Stephen J Forman, Daniel J Weisdorf, Donna Salzman, Mukta Arora, Saro H Armenian, Nature
Join now to see all

Abstracts/Posters

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopo...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Burden of Long-Term Morbidity Borne By Survivors of Acute Myeloid Leukemia (AML) Treated with Blood or Marrow Transplantation (BMT) _ a Report from the BMT Survivor St...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Stroke Risk in Blood or Marrow Transplant (BMT) Survivors _ a Report from the BMT Survivor Study (BMTSS)
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Datab...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors _ a BMT Survivor Study (BMTSS)
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A...
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) _ Long-Term Follow-up of a Phase 2a Study (KD025-208)
Daniel J. Weisdorf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Validation of Minnesota Acute Gvhd Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All Gvhd Is Created Equal
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Burden of Morbidity Borne By Survivors of Multiple Myeloma (MM) Treated with Autologous Blood or Marrow Transplant (BMT) - Results of the BMT Survivor Study (BMTSS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Grant Support

Enhancing The Safety Of Allogeneic TransplantationNational Heart, Lung, And Blood Institute2011
Clinical Transplantation Exploiting NK Cell ActivityNational Cancer Institute2005–2011
Enhanced GVHD Prophylaxis In Allogeneic Stem Cell TransplantationNational Heart, Lung, And Blood Institute2006–2010
Mt2003-23:Non-Myeloblative Haploidentical HSCT With NK Cell Infusions In High RINational Center For Research Resources2007
Non-Myeloblative Haploidentical HSCT With NK Cell Infusions In High Risk MyeloidNational Center For Research Resources2006
Enhanced GVHD Prophylaxis In Allogeneic Stem Cell Trans*National Heart, Lung, And Blood Institute2002–2005
Enhanced GVHD Prophylaxis An Allogenein Stem Cell Trans*National Heart, Lung, And Blood Institute2001
Posttransplant Immunotherapy Of Lymphoma With IL2National Cancer Institute1998–1999
Stem Cell Transplantation For Multiple MyelomaNational Cancer Institute1996–1999
Autologous Bone Marrow Transplantation For Lymphoma--ImmunotherapyNational Cancer Institute1996–1997

Professional Memberships

American Society of Clinical Oncology - ASCO
Member